Apixaban for the treatment and secondary prevention of thrombotic complications in cancer patients with impaired renal function
https://doi.org/10.17650/3034-2473-2025-2-1-58-65
Abstract
Malignant neoplasms are associated with a high risk of venous thromboembolic complications (VTEC), which worsen antitumor treatment and are the second leading cause of death after cancer progression. In patients with comorbid pathology, the risk of bleeding increases, especially during antithrombotic therapy. With a decrease in kidney function, the risk of bleeding increases 3-fold. To assess the possibilities of prescribing anticoagulant therapy to cancer patients with venous thrombosis and chronic kidney disease, a clinical observation is given.
The article presents a case of a patient with breast cancer and chronic kidney disease. For the treatment and secondary prevention of deep vein thrombosis of the lower extremities, a patient received apixaban (Eliquis), which prevented the risk of recurrent venous thrombosis without increasing the risk of bleeding. Large randomized trials have shown the efficacy and safety of apixaban in the treatment and secondary prevention of VTEC in cancer patients, including patients with chronic kidney disease. According to the results of real clinical practice, apixaban was superior to standard therapy (low molecular weight heparin + vitamin K antagonists) in both efficacy and safety in the treatment and prevention of recurrent VTEC. Thus, the anticoagulant apixaban is one of the effective and safe factor Xa inhibitors, which is characterized by a rapid onset of action and predictable pharmacokinetics; it can be considered as an affordable and effective method for the treatment and prevention of recurrent VTEC, improving the quality of life and increasing the life expectancy of cancer patients.
About the Authors
O. V. Somonova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
Oxana Vasilyevna Somonova
24 Kashirskoe Shosse, Moscow 115522
E. G. Gromova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
24 Kashirskoe Shosse, Moscow 115522
A. L. Elizarova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
24 Kashirskoe Shosse, Moscow 115522
I. V. Babkina
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
24 Kashirskoe Shosse, Moscow 115522
References
1. Trousseau A. Phlegmasia alba dolens. Clin Med Hotel-dieu Paris 1865;3:654–712.
2. Mulder F.I., Horvath-Puho E., van Es N. et al. Venous thromboembolism in cancer patients: a population-based cohort study. Blood 2021;137(14):1959–69. DOI: 10.1182/blood.2020007338
3. Falanga A., Ay C., Di Nisio M. et al. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline. Ann Oncol 2023;34(5):452–67. DOI: 10.1016/j.annonc.2022.12.014
4. Ay C., Pabinger I., Cohen A.T. Cancer-associated venous thromboembolism: burden, mechanisms, and management. Thromb Haemost 2017;117(2):219–30. DOI: 10.1160/TH16-08-061
5. Falanga A., Marchetti M. Cancer-associated thrombosis: enhanced awareness and pathophysiologic complexity. J Thromb Haemost 2023;21(6):1397–408. DOI: 10.1016/j.jtha.2023.02.029
6. Kakkos S.K., Gohel M., Baekgaard N. et al. European Society for Vascular Surgery (ESVS) 2021 clinical practice guidelines on the management of venous thrombosis. Eur J Vasc Endovasc Surg 2021;61(1):9–82. DOI: 10.1016/j.ejvs.2020.09.023
7. Falanga A., Marchetti M., Vignoli A. Coagulation and cancer: biological and clinical aspects. J Thromb Haemost 2013;11(2):223–33. DOI: 10.1111/jth.12075
8. Khorana A.A., Mackman N., Falanga A. et al. Cancer-associated venous thromboembolism. Nat Rev Dis Primers 2022;8(1):11. DOI: 10.1038/s41572-022-00336-y
9. Nickel K.F., Labberton L., Long A.T. et al. The polyphosphate/ factor XII pathway in cancer-associated thrombosis: novel perspectives for safe anticoagulation in patients with malignancies. Thromb Res 2016;141(Suppl 2):4–7. DOI: 10.1016/S0049-3848(16)30353-X
10. Shao B.Z., Yao Y., Li J.P. et al. The role of neutrophil extracellular traps in cancer. Front Oncol 2021;11:714357. DOI: 10.3389/fonc.2021.714357
11. Gran O.V., Braekhan S.K., Hansen J.B. Protrombotic genotypes and risk of venous thromboembolism in cancer. Thromb Res 2018;164(Suppl 1):12–8. DOI: 10.1016/j.thromres.2017.12.025
12. Woodruff S., Lee A.Y., Carrier M. et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in high- and low-risk patients with active cancer: a post hoc analysis of the CLOT Study. J Thromb Thrombolysis 2019;47(4):495–504. DOI: 10.1007/s11239-019-01833-w
13. Agnelli G., Bolis G., Capussotti L. et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg 2006;243(1):89–95. DOI: 10.1097/01.sla.0000193959.44677.48
14. Petrov V.I., Gorbatenko V.S., Shatalova O.V., Gerasimenko A.S. Venous thromboembolic complications in cancer patients: etiopathogenesis and prevention. Lekarstvenniy vestnik = Medicinal Bulletin 2020;14(3(79)):16–22. (In Russ.).
15. Andriashkin V.V., Somonova O.V., Panteleev M.A. et al. Diagnosis, treatment and prevention of thromboembolic complications in oncological and oncohematological patients: Textbook. Moscow: FGBOU DPO RMANPO Minzdrava Russii, 2017. 94 p. (In Russ.).
16. Nalluri S.R., Chu D., Keresztes R. et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008;300(19):2277–85. DOI: 10.1001/jama.2008.656
17. Vogel V.G., Costantino J.P., Wickerham D.L. et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 trial: preventing breast cancer. Cancer Prev Res (Phila) 2010;3(6):696–706. DOI: 10.1158/1940-6207.CAPR-10-0076
18. Khorana A.A., DeSancho M.T., Liebman H. et al. Prediction and prevention of cancer-associated thromboembolism. Oncologist 2021;26(1):e2–e7. DOI: 10.1002onco.13569
19. Fernandes C.J., Morinaga L.T.K., Alves J.L. Jr. et al. Cancerassociated thrombosis: the when, how and why. Eur Respir Rev 2019;28(151):180119. DOI: 10.1183/16000617.0119-2018
20. Watson H.G., Keeling D.M., Laffan M. et al. On behalf of British Committee for Standarts in Haemotology. Guideline on aspects of cancer-related venous thrombosis. Brit J Haematol 2015;170(5):640–8. DOI: 10.1111/bjh.13556.
21. Khorana A., Carrier M., Garcia D., Lee A.Y. Guidance for the prevention and treatment of cancer-associated venous thromboembolism. J Thromb Thrombolysis 2016;41(1):81–91. DOI: 10.1007/s11239-015-1313-4
22. Prandoni P., Lensing A.W., Piccioli A. et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100(10):3484–8. DOI: 10.1182/blood-2002-01-0108
23. Burleva E.P., Kremenevsky O.M. Prolonged anticoagulant therapy of venous thromboembolic complications: resolved issues and controversial positions. Flebologiya = Phlebology 2019;13(1):42–51. (In Russ.). DOI: 10.17116/flebo20191301142
24. Al-Samkari H., Connors J.M. Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy. Hematology Am Soc Hematol Educ Program 2019;2019(1):71–9. DOI: 10.1182/hematology.2019000369
25. Angelini D.E., Radivoyevitch T., McCrae K.R., Khorana A.A. Bleeding incidence and risk factors among cancer patients treated with anticoagulation. Am J Hematol 2019;94(7):780–5. DOI: 10.1002/ajh.25494
26. Klok F.A., Hösel V., Clemens A. et al. Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment. Eur Respir J 2016;48(5):1369–76. DOI: 10.1183/13993003.00280-2016
27. Gromova E.G., Biryukova L.S., Dzhumabaeva B.T. et al. Nephrotoxicity. Practical recommendations of RUSSCO. Part 2. Zlokachestvenniye opukholy = Malignant tumors 2024;14(3s2):184–201. DOI: 10.18027/2224-5057-2024-14-3s2-2-12
28. Saba H.I., Morelli A.G., Saba R.I. Disseminated intravascular coagulation (DIC) in cancer. Cancer Treat Res 2009;148:137–56. DOI: 10.1007/978-0-387-79962-9_9
29. Cosmai L., Porta C., Gallieni M., Perazella M.A. Onco-nephrology: a decalogue. Nephrol Dial Transplant 2016;31(4):515–9. DOI: 10.1093/ndt/gfv320
30. Elalamy I., Canon J.L., Bols A. et al. Thrombo-embolic events in cancer patients with impaired renal function. J Blood Disorders Transf 2014;5(4):1–5. DOI: 10.4172/2155-9864.1000202
31. Agnelli G., Buller H.R., Cohen A. et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013;369(9):799–808. DOI: 10.1056/NEJMoa1302507
32. Instructions for medical use of the drug Eliquis. Registration No. LP-001475. (In Russ.).
33. Agnelli G., Buller H.R., Cohen A. et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. J Thromb Haemost 2015;13(12):2187–91. DOI: 10.1111/jth.13153
34. Weycker D., Li X., Wygant G.D. et al. Effectiveness and safety of apixaban versus warfarin as outpatient treatment of venous thromboembolism in U.S. clinical practice. Thromb Haemost 2018;118(11):1951–61. DOI: 10.1055/s-0038-1673689
35. Agnelli G., Becattini C., Meyer G. et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 2020;382(17):1599–607. DOI: 10.1056/NEJMoa1915103
36. Ageno W., Vedovati M.C., Cohen A. et al. Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study. Thromb Haemost 2021;121(5):616–24. DOI: 10.1055/s-0040-1720975
37. Verso M., Munoz A., Bauersachs R. et al. Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. Eur J Cancer 2021;148:371–81. DOI: 10.1016/j.ejca.2021.02.026
38. Becattini C., Bauersachs R., Maraziti G. et al. Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. Haematologica 2022;107(7):1567–76. DOI: 10.3324/haematol.279072
39. Chang M., Yu Z., Shenker A. et al. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban. J Clin Pharmacol 2016;56(5):637–45. DOI: 10.1002/jcph.633
40. Amin A., Naeem M., Amin L. et al. Apixaban versus low molecular weight heparin in patients with cancer associated venous thromboembolism: a systematic review and meta-analysis. Ann Med Surg (Lond) 2024;86(8):4675–83. DOI: 10.1097/MS9.0000000000002147
41. Farge D., Frere C., Connors J.M. et al. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol 2022;23(7):e334–e7. DOI: 10.1016/S1470-2045(22)00160-7
42. Key N.S., Khorana A.A., Kuderer N.M. et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical Practice Guideline Update. J Clin Oncol 2023;41(16):3063–71. DOI: 10.1200/JCO.23.00294
43. Wysokinski W.E., Houghton D.E., Casanegra A.I. et al. Comparison of apixaban to rivaroxaban and enoxaparin in acute cancerassociated venous thromboembolism. Am J Hematol 2019;94(11):1185–92. DOI: 10.1002/ajh.25604
44. Computerized Registry of patients with venous thromboembolism (RIETE). Available at: www.shmedical.es
45. Agnelli G., Buller H.R., Cohen A. et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013;368(8):699–708. DOI: 10.1056/NEJMoa1207541
46. McBane R. 2nd, Loprinzi C., Zemla T. et al. Extending venous thromboembolism secondary prevention with apixaban in cancer patients. The EVE trial. J Thromb Haemost 2024;22(6):1704–14. DOI: 10.1016/j.jtha.2024.03.011
47. Stevens S.M., Woller S.C., Kreuziger L.B. et al. Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report practice. Guideline Chest 2021;160(6):e545–e608. DOI: 10.1016/j.chest.2021.07.055
48. Somonova O.V., Antukh E.A., Vardanyan A.V. et al. Thromboembolic complications. Practical recommendations of RUSSCO. Zlokachestvenniye opukholi = Malignant tumors 2024;14(3s2):202–15. (In Russ.).DOI: 10.18027/2224-5057-2024-14-3s2-2-12
Review
For citations:
Somonova O.V., Gromova E.G., Elizarova A.L., Babkina I.V. Apixaban for the treatment and secondary prevention of thrombotic complications in cancer patients with impaired renal function. Supportive Therapy in Oncology. 2025;2(1):58-65. (In Russ.) https://doi.org/10.17650/3034-2473-2025-2-1-58-65
Views:
63
Email this article 